A stack keeps each compound in its own vial, so the components stay independently adjustable. Compounds covered on their own are under Single Peptides, and compounds supplied pre-mixed in a shared vial are under Peptide Blends.
Stacks by outcome
Ten combinations grouped by the result they are put together for. Each one lists what goes in it, how much, for how many weeks, and how often — in one small table.
Every figure below is the schedule already published on that compound's own page on this site. Nothing here is a new number, and nothing here is a recommendation. Follow the compound link in any row to see the reconstitution maths, the syringe units and the full source.
Human The amount comes from an approved label or a published human trial.
Animal Dosed in animals only.
Protocol A commonly circulated research protocol. No trial establishes that exact figure.
Muscle Gain & Lean Mass
Growth-Hormone Pulse Stack
CJC-1295 makes each growth-hormone pulse bigger; ipamorelin sets the pulse off. They work on two different receptors, which is the reason they are studied side by side rather than doubling up on either one. BPC-157 is the optional third, added for tissue repair under a heavy training load rather than for growth itself.
Length: 12 weeksThen: 4 weeks offRoute: subcutaneousVials: 2–3, kept separate
What the evidence shows. CJC-1295 raised growth hormone and IGF-1 in healthy adults at 30–60 mcg/kg (Teichman et al., 2006). Ipamorelin's only published human dosing is intravenous, twice daily in hospital, for post-surgical ileus — not the schedule above. No trial has tested the pair together for muscle gain, and BPC-157 has never been dosed subcutaneously in a published human study.
Weight Loss
GLP-1 Core, with an amylin add-on
A GLP-1 slows stomach emptying and lowers appetite through the GLP-1 receptor. Cagrilintide works on the amylin receptor — a separate fullness signal — which is why the two are being trialled as a pair rather than doubling the GLP-1. Retatrutide is the swap option: it hits the GLP-1 receptor as well, so it replaces the GLP-1 rather than joining it. The dose goes up in steps because most of the nausea comes from climbing too fast.
Length: 16–68 weeksRoute: subcutaneousRhythm: same day each week
What the evidence shows. The GLP-1 steps are the approved once-weekly label's own titration; at 2.4 mg weekly it produced about 15% mean weight loss over 68 weeks. The cagrilintide amounts are from Lau et al. (Lancet 2021), but that trial climbed to 4.5 mg over 20 supervised weeks — the 16-week pace above is faster than the trial. Retatrutide is a GLP-1 agonist too, so it replaces the GLP-1 rather than joining it. In the published follow-ups, weight comes back after the drug stops.
Longevity & Cellular Aging
Course-Based Longevity Stack
Three separate targets rather than three versions of the same idea: epitalon for the pineal and telomere work, NAD+ for the coenzyme every energy step in the cell runs on, GHK-Cu for skin and connective tissue repair. It is run as a course once or twice a year, not continuously.
Length: 16 weeksRepeat: 1–2× a yearRoute: subcutaneous
What the evidence shows. Epitalon's human results come from Russian gerontology work that independent groups have not replicated. NAD+'s human evidence is for the oral precursors — NMN at 250–900 mg a day, NR at 1–2 g a day — not for injection. GHK-Cu's human evidence is topical: a 0.05% gel after laser treatment, and a cream twice daily for 12 weeks. None of the three has an outcome trial for lifespan or healthspan.
Cognitive & Focus
Semax + Selank Course
Semax is the activating half — attention and mental stamina. Selank is the settling half — anxiety and sleep quality. Both are short Russian peptides given in courses rather than continuously, and the two weeks off is part of how they are used, not an afterthought. Both are supplied here as lyophilised vials for subcutaneous use, so the course is run with a syringe like every other stack on this page.
Length: 10 days onThen: 2 weeks offRoute: subcutaneous
What the evidence shows. Selank is a registered anxiolytic in Russia and its dosing comes from that clinical literature rather than Western randomised trials. Semax has no published dose-finding trial behind the range above. For both, the published amounts come from a non-injected route, so no injectable dose is established for either — the figures above are carried across, not converted, and the Selank and Semax pages set out that limit in full. Cerebrolysin's figures come from the CASTA and CARS trial programmes, where it was given as an IV infusion to stroke and dementia patients — not to healthy people looking for focus.
Fatty Liver (MASLD/NAFLD)
Liver Fat Stack
Tesamorelin is the only compound on this page with liver fat as a measured trial endpoint. A GLP-1 sits alongside it because weight loss itself is the strongest lever on liver fat there is. Glutathione is optional and is in there for oxidative stress, not for fat.
Length: 26 weeksRoute: subcutaneousBefore and after: liver enzymes and imaging
What the evidence shows. Tesamorelin reduced liver fat in adults with HIV and fatty liver over 12 months (Stanley et al., Lancet HIV 2019); its approved indication is HIV-associated lipodystrophy, not fatty liver generally. A GLP-1 at 0.4 mg daily resolved steatohepatitis more often than placebo in a Phase 2 trial (Newsome et al., NEJM 2021). Injected glutathione has no liver trial behind it — the human evidence is oral, 250–1,000 mg a day for six months. Fatty liver is a diagnosis, and it needs imaging and blood work read by a doctor.
Addiction & Craving Support
Craving Support Stack
Two separate ideas sitting together. GLP-1 drugs keep turning up a drop in alcohol and nicotine craving as a side finding in weight trials, which is now being tested head-on. Selank is used in Russia for the anxiety side of coming off something, and is run here as a subcutaneous course. NAD+ shows up in clinics for the same purpose without controlled evidence behind it.
Length: 16 weeksStatus: exploratoryRoute: subcutaneousSupervision: medical, not optional
Read this one carefully. The craving signal for GLP-1s comes from secondary findings and small studies; a 2022 exenatide trial in alcohol use disorder missed its primary endpoint overall. The GLP-1 amounts above are the weight-loss label's, borrowed — no label covers craving. Selank's published amounts come from a non-injected route, so no injectable dose is established for it either. No peptide is an approved treatment for any addiction. Withdrawal from alcohol, benzodiazepines or opioids can be life-threatening and needs medical care; nothing on this page is a substitute for it.
Mitochondrial Health
Mitochondrial Support Stack
Three points on one pathway. SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilises it. MOTS-c is a peptide encoded inside mitochondrial DNA that pushes metabolism toward burning fat. NAD+ supplies the coenzyme the whole energy chain depends on.
Length: 8–16 weeksRoute: subcutaneousTiming: mornings
What the evidence shows. SS-31 (elamipretide) has run human trials in primary mitochondrial myopathy and Barth syndrome at 40 mg a day subcutaneously — four times the top of the schedule above — and those trials produced mixed results against their primary endpoints. MOTS-c has only ever been dosed in animals, across a very wide range. NAD+'s human evidence is the oral precursors. The schedules above are circulated protocols rather than trial findings; the compound pages carry the reconstitution arithmetic for the vial strengths Athena lists.
Injury Recovery & Joints
Repair Stack
The most commonly run pair on the list. BPC-157 is studied for gut and soft-tissue healing, TB-500 for actin regulation and cell migration into damaged tissue. Kept as two vials here so each can be adjusted on its own; the same two compounds pre-mixed into one vial are sold as Wolverine.
Length: 8–12 weeksRoute: subcutaneousVials: 2, kept separate
What the evidence shows. BPC-157's human data is a two-person IV safety pilot, a twelve-person bladder study and a sixteen-person knee case series with no control group — none of it subcutaneous, none of it for sports injury. TB-500 has no published human dosing at all. The schedule above is a circulated protocol, and the frequency is not established by any study.
Immune Resilience
Immune Resilience Stack
Thymosin alpha-1 is the anchor and the only approved drug in the group — it nudges T-cell maturation. LL-37 is the body's own antimicrobial peptide, and KPV is the anti-inflammatory tail fragment of alpha-MSH. The last two climb slowly because both are inflammation-active.
Length: 8 weeks, anchor up to 26Route: subcutaneous
What the evidence shows. Thymosin alpha-1 is approved in a number of countries as Zadaxin, and 1.6 mg twice weekly is its label dose for chronic hepatitis B — an indication, not a general immune-support claim. LL-37 and KPV have no published human dosing whatsoever; both schedules are circulated protocols.
Sleep & Overnight Recovery
Sleep & Recovery Stack
All three are dosed in the evening, for different reasons. DSIP was named for a sleep-promoting effect seen in animals. Epitalon's rationale runs through the pineal gland and melatonin rhythm. Ipamorelin is optional and goes in before bed because the natural growth-hormone pulse is biggest during deep sleep — it is not a sedative.
Length: 8 weeksRoute: subcutaneousTiming: evening
What the evidence shows. DSIP was isolated in 1977 and named for an effect in rabbits; the human sleep studies since are small, old and inconsistent, and no dose schedule is established. Epitalon's pineal rationale comes from the same unreplicated Russian work as its longevity claims. Ipamorelin's only human dosing is intravenous and in hospital.
How to use any of this. Every schedule above is copied from that compound's page, where the same numbers appear with the reconstitution maths, the syringe units and the source that produced them. The calculator converts a milligram amount into units on a U-100 syringe once you know the vial strength and the amount of water added. The dosing page covers the mechanics — reconstitution, storage, injection sites. None of it is medical advice, and none of these compounds is approved for the goals listed on this page.